Form 4: BeiGene's Global Head of R&D, Lai Wang, Reports Transaction in Company Stock

Lai Wang, Global Head of R&D at BeiGene, Ltd., reports the sale of 5,000 American Depositary Shares (ADS) at a price of $220.3548 per share on September 27, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On September 27, 2024, Lai Wang, the Global Head of R&D at BeiGene, Ltd., sold 5,000 American Depositary Shares (ADS) of the company.
• The sale was executed at a price of $220.3548 per ADS.
• This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on June 13, 2024.
• Following the reported transaction, Wang directly owns 920,920 ordinary shares.
• Wang also indirectly owns 796,965 ordinary shares through Wang Holdings LLC.
• Wang has an indirect economic interest in an indeterminable portion of RMB Shares held by the RMB Shares Employee Participation Plan, having contributed RMB10 million to the plan.
• The RMB Shares Employee Participation Plan purchased 2,069,546 RMB Shares at RMB192.6 per share (or $30.1295 based on an assumed exchange rate of $1.00 = RMB6.3924).

Sentiment

Score: 5

Explanation: This is a routine regulatory filing related to an insider transaction. The use of a 10b5-1 plan suggests a pre-planned sale, so it's neither particularly positive nor negative.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, such as the Global Head of R&D, when they trade in their company's stock. It provides transparency to the market regarding insider transactions. The use of a 10b5-1 trading plan suggests the insider is selling shares according to a pre-determined schedule to avoid accusations of trading on inside information.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders, ensuring compliance with SEC regulations.
• Rule 10b5-1 trading plans are commonly used by executives to diversify their holdings while avoiding accusations of insider trading, similar to practices at companies like Pfizer or Amgen.
• The level of detail provided in the filing is consistent with SEC requirements and industry norms.

Stakeholder Impact

• The sale of shares by a company insider could be perceived negatively by some shareholders, but the use of a pre-arranged trading plan mitigates this concern.
• The transaction has minimal direct impact on employees, customers, suppliers, or creditors.

Key Dates